The 2011 DCAT Biologics Forum will focus on trends and best practices for subcutaneous biologic drug delivery systems featuring presentations and discussion with leaders from the FDA, pharma and delivery system component supplier markets. Several key industry experts have been invited to speak at this event which will be held 14-17 March at the Waldorf-Astoria Hotel in New York City.
This is Lucio Giambattista’s first time to speak at the event and he will be joined by a panel of speakers for the afternoon session on 16 March from 1.15pm to 4.30pm in the Empire Room. Commenting on the event, Lucio Giambattista said: “Speaking at the Biologic Forum session of DCAT will give speakers the opportunity to share experiences and attendees the chance to ask questions that are relevant to their respective companies. This market is changing rapidly and as a medical device manufacturer we have a responsibility to attend events such as these to overview trends, key considerations and best practices with the interests of the end-user in mind.”
Lucio is currently executive vice president for the SHL Group and managing director of SHL Medical in the US. One of his latest responsibilities includes establishing SHL Pharma Systems, a production facility offering final assembly and packaging services in the US. His contributions to this project also mean that he will be responsible for expanding these services internationally in Europe and Asia over the coming years. Prior to joining SHL, Lucio worked for 11 years with Becton Dickinson as associate director of self-injection systems. He holds a BSME/MSME from the New Jersey Institute of Technology and has been granted several patents for pen injector and autoinjector products.